Development of Disease-Modifying Therapeutics in Alzheimer's disease and Dementia with Lewy Body (DLB)
SAK3 has been tested on two different mouse models of AD: olfactory bulbectomised, APP23 and APP knock-in. The first display cognitive impairment and depressive behaviours, while the latter have a seven-fold increase in a mutant form of amyloid beta precursor proteins in their synapses. Both exhibit elevated levels of Abeta production in the brain. Fukunaga says: 'Two months after administering our SAK3 compound to APP23 or APP knock-in mice, we observed reduced Abeta accumulations. Also, we used a novel object recognition task to assess cognitive performance and found a significant improvement.' SAK3's effects were compared to those of existing ACh release and stimulation agents ST101 and Donepezil, and shown to be significantly superior. These drugs are both produced by Fukunaga's long-term US collaborators, Sonexa Therapeutics Inc.
Keywords: ALZHEIMER'S DISEASE; COGNITIVE ENHANCEMENT; DEMENTIA; DEMENTIA WITH LEWY BODIES; DISEASE-MODIFYING THERAPEUTICS FOR ALZHEIMER'S DISEASE; NEURODEGENERATIVE DISEASE; PARKINSON'S DISEASE; PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES; SAK3; TOXICOLOGY
Document Type: Research Article
Publication date: October 15, 2018
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites